Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab Phase 3 Trial in Adult Patients with Active Proliferative Lupus Nephritis
2021-002862-42Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in lupus nephritis (LN) comparing Anifrolumab + Standard of Care with Placebo + Standard of Care (2 arms). Primary endpoint: Complete Renal Response at Week 52. Started Oct 2021; status: active.
02
Drugs
anifrolumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on 2021-002862-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002862-42.